PharmaShots | Incisive News in 3 Shots

Subscribe Now

Overactive Bladder

Urovant's Gemtesa (vibegron) Receives the US FDA's Approval for Overactive Bladder

Urovant's Gemtesa (vibegron) Receives the US FDA's Approval for Overactive Bladder

December 23, 2020

Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men

Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men

May 6, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us